163 related articles for article (PubMed ID: 21720561)
1. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.
Xie Z; Bi C; Cheong LL; Liu SC; Huang G; Zhou J; Yu Q; Chen CS; Chng WJ
PLoS One; 2011; 6(6):e21583. PubMed ID: 21720561
[TBL] [Abstract][Full Text] [Related]
2. Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Gaudichon J; Milano F; Cahu J; DaCosta L; Martens AC; Renoir JM; Sola B
PLoS One; 2014; 9(9):e107009. PubMed ID: 25255316
[TBL] [Abstract][Full Text] [Related]
3. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
4. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
5. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
7. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
8. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
10. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
12. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
13. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
15. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
18. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
[TBL] [Abstract][Full Text] [Related]
19. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
20. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
